Wells Fargo Upgrades J&J to Overweight, Lifts Target to $212 - Sees 14% Upside on Rybrevant Momentum and $55B Onshoring Bet

Wells Fargo moved Johnson & Johnson (NYSE: JNJ) up the food chain on Friday, shifting its rating from equal weight to overweight and lifting its price target to $212 from $170 - a bump that implies roughly 14% upside from current levels.

The bank's thesis centers on improving pharmaceutical sales and a string of operational shifts that could tighten margins. Analyst Larry Biegelsen points to stronger-than-expected demand for several oncology assets, including Rybrevant, and notes management's public confidence that pharma revenue will climb year-over-year from 2025 through 2027, even as sell-side models assume a slowdown. J&J's track record bolsters that claim: the company reached a $57 billion pharma revenue milestone for 2025 ahead of schedule.

Wells Fargo also highlighted two margin-related themes. First, the drag from tariff dynamics that showed up last April looks to be easing, which should help operating leverage. Second, J&J's large-scale push to onshore drug production - a $55 billion investment in U.S. research and manufacturing over the next four years plus a $2 billion expansion in North Carolina - lays the groundwork for fewer trade-related swings down the line.

In short: rising sales momentum for cancer drugs, a softer tariff backdrop, and a heavy lift on domestic manufacturing underpin the upgrade. The bank believes those factors could lift valuation if pharma performance outpaces consensus expectations and if pricing risks remain contained, particularly as the company navigates Stelara's loss of exclusivity.

How the market reacted: shares ticked up about 1% in premarket trades on Friday and have climbed roughly 16% over the last 12 months. Coverage is mixed but tilted positive - 14 of 27 analysts covering the name carry buy or strong buy ratings.

Whether the new price target and the domestic-manufacturing bet are enough to keep momentum going will depend on execution and continued top-line traction from its newer oncology franchises. Worth watching: Rybrevant uptake, the pace of margin improvement as tariff effects normalize, and any early results from the U.S. manufacturing ramp.